Tumours not expressing an abundance of SSTR-2 over SSTR-5 subtypes may have reduced response to these agents and may, in fact, experience preferential suppression of glucagon over insulin, leading to hypoglycaemia (Bertherat et al. 2003). The gene discussed is SSTR2; the disease is neoplasm.